Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 6Radiosurgery 6Nivolumab 6Magnetic Resonance Spectroscopy 6Ifosfamide 5Bevacizumab 5cabozantinib 4Sunitinib 4Sirolimus 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Carboplatin 4Specimen Handling 3Sorafenib 3Paclitaxel 3Melphalan 3Ipilimumab 3Cyclophosphamide 3Busulfan 3temsirolimus 2lenvatinib 2etoposide phosphate 2cediranib 2belzutifan 2alectinib 2Trastuzumab 2Thiotepa 2Stem Cell Transplantation 2Radiotherapy 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × guadecitabine × CNS × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡